Earlier Monday, Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.00-$9.00 to $8.50-$9.50 vs $9.40 Est; Raises FY2026 Sales Guidance from $245M-$285M to $270M-$310M vs $266.714M Est